Skip to main content
Top
Published in: Journal of Inflammation 1/2009

Open Access 01-12-2009 | Research

Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue

Authors: Joke Patou, Gabriele Holtappels, Karen Affleck, Philippe Gevaert, Claudina Perez-Novo, Paul Van Cauwenberge, Claus Bachert

Published in: Journal of Inflammation | Issue 1/2009

Login to get access

Abstract

Background

The mast cell is a crucial effector cell in allergic rhinitis and other inflammatory diseases. During the acute allergic reaction preformed mediators such as histamine, but also de novo produced mediators such as leukotrienes (LTC4/D4/E4) and prostaglandins (PGD2) are released. Mast cells represent targets for therapeutic intervention, and thus a human ex-vivo model to stimulate mast cells taken from mucosal sites would be instrumental for drug intervention studies. We have aimed to activate mast cells within ex-vivo human nasal tissue by IgE/anti-IgE specific (ε chain specific) stimulations and in this respect to test the usability of nasal polyps versus inferior turbinates

Methods

Biopsy samples were collected from patients with nasal polyps and inferior turbinates from patients who underwent sinus or septal surgery. Tissue fragments were primed with IgE 1 μg/ml for 60 minutes and then stimulated for 30 minutes with tissue culture medium (negative control), anti-IgE 10 μg/ml, anti-IgE 30 μg/ml and ionomycin 10 μM (positive control). Histamine, leukotrienes and PGD2 were measured in supernatants. To help provide an understanding of the extent of the response, the number of tryptase and FcεRIα positive cells was evaluated by means of immunohistochemistry and the FcεRIα-chain was measured by means of quantitative PCR in the nasal polyp and inferior turbinate tissues. Finally, the correlation between IgE concentrations in the nasal tissue and the release of mediators was analysed.

Results

Stimulations with anti-IgE on IgE-primed nasal tissue fragments lead to a concentration-dependent release of histamine, leukotrienes and PGD2. The release of these early phase mediators was significantly higher in nasal polyps compared to inferior turbinates, although tryptase, FcεRIα positive cells and FcεRIα-chain transcripts were equally present in both groups. No correlation was found between baseline concentrations of IgE, and the release of histamine, LTC4/LTD4/LTE4 and PGD2 after stimulation.

Conclusion

This human nasal challenge model mimics the allergic early phase reaction. The release of histamine, cys-leukotrienes and PGD2 was significantly higher in nasal polyps versus inferior turbinates, however, this observation could not be explained by differences in mast cell or FcεRI+ cell numbers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001, 108: S147-334. 10.1067/mai.2001.118891.PubMedCrossRef Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001, 108: S147-334. 10.1067/mai.2001.118891.PubMedCrossRef
2.
go back to reference Skoner DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001, 108: S2-8. 10.1067/mai.2001.115569.PubMedCrossRef Skoner DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001, 108: S2-8. 10.1067/mai.2001.115569.PubMedCrossRef
3.
go back to reference Hansen I, Klimek L, Mosges R, Hormann K: Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2004, 4: 159-163. 10.1097/00130832-200406000-00004.PubMedCrossRef Hansen I, Klimek L, Mosges R, Hormann K: Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2004, 4: 159-163. 10.1097/00130832-200406000-00004.PubMedCrossRef
4.
go back to reference Taurog JD, Mendoza GR, Hook WA, Siraganian RP, Metzger H: Noncytotoxic IgE-mediated release of histamine and serotonin from murine mastocytoma cells. J Immunol. 1977, 119: 1757-1761.PubMed Taurog JD, Mendoza GR, Hook WA, Siraganian RP, Metzger H: Noncytotoxic IgE-mediated release of histamine and serotonin from murine mastocytoma cells. J Immunol. 1977, 119: 1757-1761.PubMed
5.
go back to reference Barsumian EL, McGivney A, Basciano LK, Siraganian RP: Establishment of four mouse mastocytoma cell lines. Cell Immunol. 1985, 90: 131-141. 10.1016/0008-8749(85)90175-3.PubMedCrossRef Barsumian EL, McGivney A, Basciano LK, Siraganian RP: Establishment of four mouse mastocytoma cell lines. Cell Immunol. 1985, 90: 131-141. 10.1016/0008-8749(85)90175-3.PubMedCrossRef
6.
go back to reference Gregory GD, Brown MA: Mast cells in allergy and autoimmunity: implications for adaptive immunity. Methods Mol Biol. 2006, 315: 35-50.PubMed Gregory GD, Brown MA: Mast cells in allergy and autoimmunity: implications for adaptive immunity. Methods Mol Biol. 2006, 315: 35-50.PubMed
7.
go back to reference Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988, 12: 345-355. 10.1016/0145-2126(88)90050-1.PubMedCrossRef Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988, 12: 345-355. 10.1016/0145-2126(88)90050-1.PubMedCrossRef
8.
go back to reference Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD: Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003, 27: 677-682. 10.1016/S0145-2126(02)00343-0.PubMedCrossRef Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD: Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003, 27: 677-682. 10.1016/S0145-2126(02)00343-0.PubMedCrossRef
9.
go back to reference Pawankar R, Okuda M, Yssel H, Okumura K, Ra C: Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest. 1997, 99: 1492-1499. 10.1172/JCI119311.PubMedPubMedCentralCrossRef Pawankar R, Okuda M, Yssel H, Okumura K, Ra C: Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest. 1997, 99: 1492-1499. 10.1172/JCI119311.PubMedPubMedCentralCrossRef
10.
go back to reference Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, Lebel B: Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy. 2002, 57: 1067-1070. 10.1034/j.1398-9995.2002.23452.x.PubMedCrossRef Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, Lebel B: Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy. 2002, 57: 1067-1070. 10.1034/j.1398-9995.2002.23452.x.PubMedCrossRef
11.
go back to reference Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L: Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy. 2005, 60: 80-85. 10.1111/j.1398-9995.2005.00642.x.PubMedCrossRef Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L: Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy. 2005, 60: 80-85. 10.1111/j.1398-9995.2005.00642.x.PubMedCrossRef
12.
go back to reference Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, Costa JJ, Galli SJ: IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol. 1999, 162: 5455-5465.PubMed Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, Costa JJ, Galli SJ: IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol. 1999, 162: 5455-5465.PubMed
13.
go back to reference Fokkens W, Lund V, Bachert C, Clement P, Helllings P, Holmstrom M, Jones N, Kalogjera L, Kennedy D, Kowalski M: EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy. 2005, 60: 583-601. 10.1111/j.1398-9995.2005.00830.x.PubMedCrossRef Fokkens W, Lund V, Bachert C, Clement P, Helllings P, Holmstrom M, Jones N, Kalogjera L, Kennedy D, Kowalski M: EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy. 2005, 60: 583-601. 10.1111/j.1398-9995.2005.00830.x.PubMedCrossRef
14.
go back to reference Jensen BM, Dissing S, Skov PS, Poulsen LK: A comparative study of the FcepsilonRI molecule on human mast cell and basophil cell lines. Int Arch Allergy Immunol. 2005, 137: 93-103. 10.1159/000085464.PubMedCrossRef Jensen BM, Dissing S, Skov PS, Poulsen LK: A comparative study of the FcepsilonRI molecule on human mast cell and basophil cell lines. Int Arch Allergy Immunol. 2005, 137: 93-103. 10.1159/000085464.PubMedCrossRef
15.
go back to reference Perez-Novo CA, Claeys C, Speleman F, Van Cauwenberge P, Bachert C, Vandesompele J: Impact of RNA quality on reference gene expression stability. Biotechniques. 2005, 39: 52-10.2144/05391BM05. 54, 56PubMedCrossRef Perez-Novo CA, Claeys C, Speleman F, Van Cauwenberge P, Bachert C, Vandesompele J: Impact of RNA quality on reference gene expression stability. Biotechniques. 2005, 39: 52-10.2144/05391BM05. 54, 56PubMedCrossRef
16.
go back to reference Gevaert P, Bachert C, Holtappels G, Novo CP, Heyden Van der J, Fransen L, Depraetere S, Walter H, van Cauwenberge P, Tavernier J: Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003, 58: 371-379. 10.1034/j.1398-9995.2003.00110.x.PubMedCrossRef Gevaert P, Bachert C, Holtappels G, Novo CP, Heyden Van der J, Fransen L, Depraetere S, Walter H, van Cauwenberge P, Tavernier J: Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003, 58: 371-379. 10.1034/j.1398-9995.2003.00110.x.PubMedCrossRef
17.
go back to reference Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P: Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001, 107: 607-614. 10.1067/mai.2001.112374.PubMedCrossRef Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P: Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001, 107: 607-614. 10.1067/mai.2001.112374.PubMedCrossRef
18.
go back to reference Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C, Nilsson K, Hellman L: Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol. 1994, 39: 489-498. 10.1111/j.1365-3083.1994.tb03404.x.PubMedCrossRef Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C, Nilsson K, Hellman L: Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol. 1994, 39: 489-498. 10.1111/j.1365-3083.1994.tb03404.x.PubMedCrossRef
19.
go back to reference Kirshenbaum AS, Metcalfe DD: Growth of human mast cells from bone marrow and peripheral blood-derived CD34+ pluripotent progenitor cells. Methods Mol Biol. 2006, 315: 105-112.PubMed Kirshenbaum AS, Metcalfe DD: Growth of human mast cells from bone marrow and peripheral blood-derived CD34+ pluripotent progenitor cells. Methods Mol Biol. 2006, 315: 105-112.PubMed
20.
go back to reference Saito H: Culture of human mast cells from hemopoietic progenitors. Methods Mol Biol. 2006, 315: 113-122.PubMed Saito H: Culture of human mast cells from hemopoietic progenitors. Methods Mol Biol. 2006, 315: 113-122.PubMed
21.
go back to reference Denburg JA: Cytokine-induced human basophil/mast cell growth and differentiation in vitro. Springer Semin Immunopathol. 1990, 12: 401-414. 10.1007/BF00225326.PubMedCrossRef Denburg JA: Cytokine-induced human basophil/mast cell growth and differentiation in vitro. Springer Semin Immunopathol. 1990, 12: 401-414. 10.1007/BF00225326.PubMedCrossRef
22.
go back to reference Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M: Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol. 1996, 157: 343-350.PubMed Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M: Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol. 1996, 157: 343-350.PubMed
23.
go back to reference Lebel B, Crampette L, Vergnes C, Campbell AM, Bousquet J: Inhibition of mediator release from dispersed nasal polyp cells by cyclosporin A. Int Arch Allergy Immunol. 1998, 116: 284-287. 10.1159/000023957.PubMedCrossRef Lebel B, Crampette L, Vergnes C, Campbell AM, Bousquet J: Inhibition of mediator release from dispersed nasal polyp cells by cyclosporin A. Int Arch Allergy Immunol. 1998, 116: 284-287. 10.1159/000023957.PubMedCrossRef
24.
go back to reference Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, Jouvin MH, Schmitt-Egenolf M, Kraft D, Kinet JP, Stingl G: Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol. 1996, 157: 607-616.PubMed Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, Jouvin MH, Schmitt-Egenolf M, Kraft D, Kinet JP, Stingl G: Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol. 1996, 157: 607-616.PubMed
25.
go back to reference Seminario MC, Saini SS, MacGlashan DW, Bochner BS: Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol. 1999, 162: 6893-6900.PubMed Seminario MC, Saini SS, MacGlashan DW, Bochner BS: Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol. 1999, 162: 6893-6900.PubMed
26.
go back to reference Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, Gleich GJ: Does IgE bind to and activate eosinophils from patients with allergy?. J Immunol. 1999, 162: 6901-6911.PubMed Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, Gleich GJ: Does IgE bind to and activate eosinophils from patients with allergy?. J Immunol. 1999, 162: 6901-6911.PubMed
27.
go back to reference KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ: Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol. 2000, 106: 677-686. 10.1067/mai.2000.109621.PubMedCrossRef KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ: Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol. 2000, 106: 677-686. 10.1067/mai.2000.109621.PubMedCrossRef
28.
go back to reference Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM: Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985, 313: 65-70.PubMedCrossRef Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM: Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985, 313: 65-70.PubMedCrossRef
29.
go back to reference Schleimer RP, Fox CC, Naclerio RM, Plaut M, Creticos PS, Togias AG, Warner JA, Kagey-Sobotka A, Lichtenstein LM: Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol. 1985, 76: 369-374. 10.1016/0091-6749(85)90656-6.PubMedCrossRef Schleimer RP, Fox CC, Naclerio RM, Plaut M, Creticos PS, Togias AG, Warner JA, Kagey-Sobotka A, Lichtenstein LM: Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol. 1985, 76: 369-374. 10.1016/0091-6749(85)90656-6.PubMedCrossRef
30.
go back to reference Ruhno J, Howie K, Anderson M, Andersson B, Vanzieleghem M, Hitch D, Lapp P, Denburg J, Dolovich J: The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. Allergy. 1990, 45: 370-374. 10.1111/j.1398-9995.1990.tb00513.x.PubMedCrossRef Ruhno J, Howie K, Anderson M, Andersson B, Vanzieleghem M, Hitch D, Lapp P, Denburg J, Dolovich J: The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. Allergy. 1990, 45: 370-374. 10.1111/j.1398-9995.1990.tb00513.x.PubMedCrossRef
31.
go back to reference Otsuka H, Ohkubo K, Seki H, Ohnishi M, Fujikura T: Mast cell quantitation in nasal polyps, sinus mucosa and nasal turbinate mucosa. J Laryngol Otol. 1993, 107: 418-422. 10.1017/S002221510012331X.PubMedCrossRef Otsuka H, Ohkubo K, Seki H, Ohnishi M, Fujikura T: Mast cell quantitation in nasal polyps, sinus mucosa and nasal turbinate mucosa. J Laryngol Otol. 1993, 107: 418-422. 10.1017/S002221510012331X.PubMedCrossRef
32.
go back to reference Drake-Lee AB, Chevreton E, Lowe D: The effects of different fixations on the distribution and numbers of mast cells in patients with nasal polyps. J Laryngol Otol. 1988, 102: 1099-1101.PubMedCrossRef Drake-Lee AB, Chevreton E, Lowe D: The effects of different fixations on the distribution and numbers of mast cells in patients with nasal polyps. J Laryngol Otol. 1988, 102: 1099-1101.PubMedCrossRef
33.
go back to reference Kitapci F, Muluk NB, Atasoy P, Koc C: Role of mast and goblet cells in the pathogenesis of nasal polyps. J Otolaryngol. 2006, 35: 122-132. 10.2310/7070.2005.5004.PubMedCrossRef Kitapci F, Muluk NB, Atasoy P, Koc C: Role of mast and goblet cells in the pathogenesis of nasal polyps. J Otolaryngol. 2006, 35: 122-132. 10.2310/7070.2005.5004.PubMedCrossRef
34.
go back to reference Sasaki Y: Distribution of the degranulated and non-degranulated mast cells in nasal polyp. Acta Otolaryngol Suppl. 1986, 430: 34-38.PubMed Sasaki Y: Distribution of the degranulated and non-degranulated mast cells in nasal polyp. Acta Otolaryngol Suppl. 1986, 430: 34-38.PubMed
35.
go back to reference Kawabori S, Denburg JA, Schwartz LB, Irani AA, Wong D, Jordana G, Evans S, Dolovich J: Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. Am J Respir Cell Mol Biol. 1992, 6: 37-43.PubMedCrossRef Kawabori S, Denburg JA, Schwartz LB, Irani AA, Wong D, Jordana G, Evans S, Dolovich J: Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. Am J Respir Cell Mol Biol. 1992, 6: 37-43.PubMedCrossRef
36.
go back to reference Finotto S, Dolovich J, Denburg JA, Jordana M, Marshall JS: Functional heterogeneity of mast cells isolated from different microenvironments within nasal polyp tissue. Clin Exp Immunol. 1994, 95: 343-350.PubMedPubMedCentralCrossRef Finotto S, Dolovich J, Denburg JA, Jordana M, Marshall JS: Functional heterogeneity of mast cells isolated from different microenvironments within nasal polyp tissue. Clin Exp Immunol. 1994, 95: 343-350.PubMedPubMedCentralCrossRef
37.
go back to reference Di Lorenzo G, Drago A, Esposito Pellitteri M, Candore G, Colombo A, Gervasi F, Pacor ML, Purello D'Ambrosio F, Caruso C: Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. Int Arch Allergy Immunol. 2001, 125: 164-175. 10.1159/000053811.PubMedCrossRef Di Lorenzo G, Drago A, Esposito Pellitteri M, Candore G, Colombo A, Gervasi F, Pacor ML, Purello D'Ambrosio F, Caruso C: Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. Int Arch Allergy Immunol. 2001, 125: 164-175. 10.1159/000053811.PubMedCrossRef
38.
go back to reference Gevaert P, Holtappels G, Johansson SG, Cuvelier C, Cauwenberge P, Bachert C: Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue. Allergy. 2005, 60: 71-79. 10.1111/j.1398-9995.2004.00621.x.PubMedCrossRef Gevaert P, Holtappels G, Johansson SG, Cuvelier C, Cauwenberge P, Bachert C: Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue. Allergy. 2005, 60: 71-79. 10.1111/j.1398-9995.2004.00621.x.PubMedCrossRef
39.
go back to reference Borkowski TA, Jouvin MH, Lin SY, Kinet JP: Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol. 2001, 167: 1290-1296.PubMedCrossRef Borkowski TA, Jouvin MH, Lin SY, Kinet JP: Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol. 2001, 167: 1290-1296.PubMedCrossRef
40.
go back to reference MacGlashan D, Xia HZ, Schwartz LB, Gong J: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol. 2001, 70: 207-218.PubMed MacGlashan D, Xia HZ, Schwartz LB, Gong J: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol. 2001, 70: 207-218.PubMed
41.
go back to reference Kubo S, Matsuoka K, Taya C, Kitamura F, Takai T, Yonekawa H, Karasuyama H: Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface. J Immunol. 2001, 167: 3427-3434.PubMedCrossRef Kubo S, Matsuoka K, Taya C, Kitamura F, Takai T, Yonekawa H, Karasuyama H: Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface. J Immunol. 2001, 167: 3427-3434.PubMedCrossRef
42.
go back to reference Lowman MA, Rees PH, Benyon RC, Church MK: Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol. 1988, 81: 590-597. 10.1016/0091-6749(88)90199-6.PubMedCrossRef Lowman MA, Rees PH, Benyon RC, Church MK: Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol. 1988, 81: 590-597. 10.1016/0091-6749(88)90199-6.PubMedCrossRef
43.
go back to reference Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB: Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA. 1986, 83: 4464-4468. 10.1073/pnas.83.12.4464.PubMedPubMedCentralCrossRef Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB: Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA. 1986, 83: 4464-4468. 10.1073/pnas.83.12.4464.PubMedPubMedCentralCrossRef
Metadata
Title
Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue
Authors
Joke Patou
Gabriele Holtappels
Karen Affleck
Philippe Gevaert
Claudina Perez-Novo
Paul Van Cauwenberge
Claus Bachert
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2009
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-6-11

Other articles of this Issue 1/2009

Journal of Inflammation 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine